Histocompatibility & HLA Testing Billing Services To Recover Every Dollar You've Earned

Most histocompatibility labs and transplant programs lose 15-20% of collectible revenue annually; not from low testing volume, but standalone CPT billing of services that should flow through the organ acquisition cost center, living donor identity errors, and chimerism testing denials that generalist billers miss entirely. TransLabs’ certified histocompatibility billing specialists close those gaps with a 98% clean claims rate and 30% faster A/R.
Histocompatibility and HLA Testing Billing Services
0%
Client Retention Rate
0%
First-Pass Claim Rate
0%
Avg. Revenue Growth
0%
Avg. Denial Reduction

Why Histocompatibility Laboratories Lose Revenue Every Single Day

Histocompatibility billing breaks from standard lab medicine: solid organ transplant HLA services flow through the hospital’s organ acquisition cost center on a reasonable-cost basis via the Medicare cost report, while stem cell HLA typing bundles into DRG/APC payment. Get the pathway wrong, and a clinically necessary test yields zero reimbursement. Generalist billers rarely grasp this distinction; the loss compounds until a cost report reconciliation reveals it.

The Five Revenue Leaks Most Histocompatibility Labs Don't Know They Have

Standalone CPT Billing of Solid Organ Transplant HLA Services

Living Donor Identity & Billing Errors

Under-Captured Antibody Interpretation Revenue

Chimerism Testing Frequency & Timing Denials

Kidney Paired Donation Cross-Hospital Billing Errors

Histocompatibility and HLA Testing Billing Services

Every Histocompatibility Testing Category, Billed Correctly; From Typing to Transplant

From molecular HLA typing to post-transplant chimerism monitoring, our AAPC and AHIMA certified coders know the CPT coding rules, the organ acquisition billing pathway, and the payer-specific medical necessity requirements for every category of histocompatibility and transplant immunology testing.

HLA Molecular Typing --- Low & High Resolution

CPT 81370--81383

Molecular HLA Class I and II typing at low resolution/antigen equivalent level (81370) through high-resolution allele-level typing of individual loci (81371-81383), used for transplant donor-recipient matching and unrelated donor registry searches.

Key Billing Consideration

Resolution level billed must match what was actually performed and reported --- billing a high-resolution code when only antigen-level typing was completed is a frequent and easily audited discrepancy.

Crossmatch Testing --- Cytotoxicity & Flow Cytometry

CPT 86805--86806, 86825--86826

Complement-dependent cytotoxicity crossmatch, with (86805) and without (86806) antihuman globulin enhancement, and flow cytometry crossmatch for T-cell and B-cell reactivity (86825, 86826), used to detect preformed donor-specific antibodies before transplant.

Key Billing Consideration

The specific crossmatch method performed, cytotoxicity versus flow cytometry, must match the CPT code billed exactly, and the number of donor-recipient pairs tested must be reflected in the units submitted.

Panel Reactive Antibody & Solid Phase Antibody Testing

CPT 86807--86808, 86828--86830

Cytotoxic percent reactive antibody screening (86807, 86808) and solid phase single antigen bead assays used to identify and characterize specific anti-HLA antibodies (86828-86830), central to calculating a patient's sensitization level while awaiting transplant.

Key Billing Consideration

Single antigen bead testing generates a large volume of interpretive data per specimen --- undercounting the antibody specificities actually identified and reported is one of the most common sources of uncollected revenue in this category.

Virtual Crossmatch & Donor-Specific Antibody

(DSA) Monitoring

Ongoing post-transplant surveillance for donor-specific antibodies using solid phase assays, combined with molecular donor and recipient typing data to support virtual crossmatch determinations without requiring a live donor specimen.

Key Billing Consideration

Virtual crossmatch relies on precise mapping of molecular typing results to UNOS antigen equivalents --- documentation gaps in that mapping process can affect both clinical decision-making and the defensibility of the billed interpretation.

Chimerism Testing for Post-Transplant Engraftment

CPT 81265--81266

Short tandem repeat-based chimerism analysis without cell selection (81265) and with cell subset selection (81266), used after allogeneic stem cell transplant to monitor donor cell engraftment and detect early signs of graft failure or relapse.

Key Billing Consideration

Chimerism testing tied to a documented clinical indication, such as monitoring for relapse or graft failure, is far less likely to be denied than testing billed on a fixed post-transplant calendar schedule without that link.

HLA Disease Association & Non-Transplant Testing

CPT 81370--81383 (select codes)

Targeted HLA allele testing performed for non-transplant clinical indications, including HLA-B27 for suspected ankylosing spondylitis and related spondyloarthropathies, and HLA-DQ2/DQ8 testing to support or exclude a celiac disease diagnosis.

Key Billing Consideration

These tests use the same molecular typing CPT codes as transplant HLA typing but carry entirely different medical necessity documentation --- claims must clearly reflect the non-transplant clinical indication to avoid confusion with transplant-related billing.

Solid Organ Transplant Histocompatibility Testing

Organ Acquisition Cost Center Billing

HLA typing, crossmatch, and antibody testing performed in connection with a covered solid organ transplant (kidney, heart, lung, liver, pancreas, intestinal), captured as an organ acquisition cost rather than billed as a standalone laboratory claim.

Key Billing Consideration

Medicare denies standalone CPT claims for these services outright when tied to a covered solid organ transplant --- the cost must instead be captured through the transplant hospital's organ acquisition cost center and reported on the Medicare cost report.

Hematopoietic Stem Cell Transplant Donor

Recipient HLA Matching

High-resolution HLA typing and unrelated donor registry search support for allogeneic stem cell and bone marrow transplant, including the molecular-to-antigen mapping required for national registry matching algorithms.

Key Billing Consideration

HLA typing for an allogeneic stem cell transplant is bundled into the MS-DRG payment for inpatient transplants or the OPPS APC payment for outpatient transplants --- it is not separately payable, and billing it as a standalone claim results in denial.

Our Laboratory RCM Services

TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.

Proficient Across Multiple LIS & EHRs to Simplify Your
Laboratory Management

ChartLogic
Collaborate md
Greenway health
Haemonetics
jane
cgm Labdaq
Modmed
open emr
Harris Data Integrity Solutions
siemens healthineers
Tebra
Oracle Health
Confience
Power path
Benchmark solutions
Xifin
Psyche Systems
veradigm
Turemed Lis
Telcor
Practice pro
novo path
Nextgen Healthcare
Next tech
meditech
Advanced data systems corporation
Logilab
Labware
Lab vantage
labs os
Epic
Dr Chrono
dendi
Corepoint
clinisys
Care Cloud
apex healthware
clinisys copathplus
Advanced md
softlab
athenaone

Serving Labs Across The United States

TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.

Medicare Compliance for Histocompatibility & HLA Testing

Histocompatibility billing compliance centers on a single fact most generalist billers never learn: solid organ transplant HLA services aren’t paid through ordinary fee-for-service claims at all. They flow through the transplant hospital’s organ acquisition cost center and get reimbursed on a reasonable-cost basis through the Medicare cost report, a completely different mechanism from the CPT-based billing that governs almost every other lab specialty. Getting this wrong doesn’t just create a denial, it can misstate a hospital’s entire cost report.
Organ Acquisition Cost Center (OACC) Reporting

HLA typing, crossmatch, and antibody testing performed for a covered solid organ transplant must be captured as an organ acquisition cost and reported on the transplant hospital's Medicare cost report, not billed as a standalone laboratory claim. Standalone CPT claims for these services in a solid organ transplant context are denied automatically. TransLabs routes these services correctly from the start and supports the documentation your finance team needs for cost report preparation.

Standard Acquisition Charge (SAC) Methodology

Transplant hospitals must establish separate standard acquisition charges for living and deceased donor organs, reflecting the average reasonable and necessary costs of organ procurement, including histocompatibility testing. TransLabs ensures histocompatibility testing costs are properly captured and categorized to support accurate SAC calculation.

Stem Cell Transplant HLA Bundling Under MS-DRG & OPPS

HLA typing performed in connection with an allogeneic stem cell transplant is bundled into the MS-DRG payment for inpatient transplants or the OPPS APC payment for outpatient transplants, with no separate payment available. TransLabs confirms bundling status before a claim is submitted to prevent an automatic denial.

Living Donor Billing Under the Recipient's Medicare Beneficiary Identifier

Living donor complications and related testing costs are billed under the transplant recipient's Medicare Beneficiary Identifier, with no deductible or coinsurance liability to the donor. TransLabs verifies the correct beneficiary identifier is used on every living donor-related claim.

Kidney Paired Donation Cross-Hospital Billing Protocols

When a donor is evaluated at one transplant hospital and matched to a recipient at another through a paired exchange program, specific CMS-compliant billing sequences govern which hospital bills which costs and when. TransLabs applies these protocols correctly to prevent both reimbursement gaps and cost report inconsistencies.

UNOS/OPTN Data Reporting & Molecular-to-Antigen Mapping

Histocompatibility labs must accurately map molecular HLA typing results to UNOS antigen equivalents for entry into the national organ matching system, a process with real financial and clinical stakes for accurate donor-recipient matching. TransLabs supports documentation practices that keep this mapping process defensible.

OIG Monitoring of Organ Acquisition Cost Centers

Organ acquisition cost centers have been repeatedly audited by the OIG for cost-shifting between pre- and post-transplant activities and for improperly allocated staff time. TransLabs builds documentation practices around these known audit risk patterns to support your transplant program's compliance posture.

We Bill Only for Laboratories and That Difference Shows in Every Metric We Track

Most billing companies have never encountered organ acquisition cost center billing and don’t know it exists, let alone how to route a claim through it correctly. TransLabs was built for laboratory billing exclusively, and our histocompatibility team understands the fee-for-service side and the cost-report side of this specialty; no divided attention, no generalist assumptions.

Histocompatibility & Transplant Immunology-Exclusive Specialization

Transplant immunology is the focus; HLA typing, crossmatch, and cost center documentation, done right.

98% First-Pass Clean Claims Rate

98%+ clean claims rate across all lab clients with fewer denials, faster payments, stronger cash flow.

Organ Acquisition Cost Center Expertise

We know standard acquisition charges, donor cost reporting, and MS-DRG/OPPS bundling for HLA typing; expertise generalist billers simply don’t have.

High-Complexity Test Architecture

Purpose-built for histocompatibility; typing resolution, crossmatch methods, antibody interpretation, not retrofitted from routine chemistry.

No Long-Term Contracts

Month-to-month, results-based partnership with measurable improvement in 90 days, no exit fees, just 30 days’ notice.

Transparent Reporting

Monthly dashboards with full visibility of clean claims rate, denial trends, A/R aging, and root cause analysis, no surprises.

Get Your Lab's Custom Revenue Recovery Plan

Schedule a call with our histocompatibility billing specialist. We’ll review your billing pathway accuracy, organ acquisition cost documentation, non-transplant testing claims, and A/R days.

What Our Clients Say?

Linda Hutchinson
Linda Hutchinson
Laboratory Director
Our NGS panel denials dropped from 32% to under 6% within three months. TransLabs' expertise with molecular tier codes, prior authorization management, and LCD compliance has been invaluable. They understand the nuances of genetic testing billing that our previous vendor completely missed.
Peter Wozniak
Peter Wozniak
Pathologist & Laboratory Owner
We've worked with three other billing companies over the years. TransLabs is the only one that truly understands complex surgical pathology coding, immunohistochemistry billing, and the nuances of TC/PC modifiers. Clean claims rate improved to 99%, and our dermatopathology reimbursement increased 27%.
James Patton
James Patton
Cytogenetics Laboratory Manager
Before TransLabs, our FISH and karyotype claims were a constant struggle with denials and underpayments. Their coders actually understand probe configurations, complexity levels, and when to use 88271 versus 88275. Our cytogenetics revenue increased 34% in the first year.

Book Consultation Today!

Stop Leaving Reimbursements on the Table

Join 500+ diagnostic and clinical laboratories that trust TransLabs, the laboratory billing company built for growth. Start with our complimentary claims audit. Our histocompatibility billing specialists will review your billing pathway accuracy, your organ acquisition cost documentation, and your non-transplant HLA testing claims to show you exactly what’s recoverable.

Dedicated billing specialist assigned to your lab or transplant program

Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers

Uncover your top 3 revenue leaks (standalone billing errors, documentation gaps, timing denials)

Custom strategy tailored to your test menu and LIS/billing software

Live in 24 hours with no contracts and no upfront fees

Pay only a percentage of what we collect for you

Frequently Asked Questions

Why can't we bill HLA typing and crossmatch testing as regular CPT claims for transplant patients?

For a covered solid organ transplant, Medicare treats HLA typing, crossmatch, and antibody testing as organ acquisition costs, reimbursed on a reasonable-cost basis through the transplant hospital’s Medicare cost report, not as standalone fee-for-service laboratory claims. Billing these services as standard CPT claims in that context results in an automatic denial.
No. HLA-B27 testing for suspected ankylosing spondylitis, HLA-DQ2/DQ8 testing for celiac disease, and other non-transplant HLA testing are billed as standard fee-for-service laboratory claims using the same CPT codes, but with entirely different medical necessity documentation than transplant-related testing.
HLA typing performed for an allogeneic stem cell transplant is bundled into the MS-DRG payment when the transplant occurs in the inpatient setting, or into the OPPS APC payment in the outpatient setting. It is not separately payable, so it should not be billed as a standalone claim.
Typically 6-9% of net collections for non-transplant fee-for-service testing, with organ acquisition cost documentation support often structured separately given its connection to hospital cost reporting rather than standard claims. TransLabs prices transparently based on your specific mix of transplant and non-transplant testing.
Living donor complications and related testing costs are billed under the transplant recipient’s Medicare Beneficiary Identifier, not the donor’s, and the donor has no deductible or coinsurance liability for these services.
Industry benchmark for non-transplant HLA and disease-association testing runs 8-12%. TransLabs clients typically operate below 4%. Common denial drivers include documentation mismatches between transplant and non-transplant testing pathways and chimerism testing frequency issues.
Yes. TransLabs works with your finance and transplant administration teams to identify misrouted claims and correct documentation practices going forward, though correcting prior cost reports is a process your hospital’s cost report preparer and compliance counsel should be directly involved in.
Most labs see results within 60-90 days: billing pathway correction and credentialing in the first 30 days, non-transplant denial improvement by day 60, and by day 90, accurate routing of transplant-related services with a documented improvement in overall billing accuracy.

Your Trusted Lab Billing Partner

Book Your Free Consultation

Book Consultation Today!

Book Consultation Today!